Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Roche Holdings ADR RHHBY

Healthcare
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue... see more

Recent & Breaking News (OTCQX:RHHBY)

Alimera's Commercial Steroid Implant For Diabetic Macular Edema, Explored

Benzinga.com  April 30, 2017

New Data at AAN Reinforce Clinical Benefit of Genentech’s OCREVUS (Ocrelizumab) for Relapsing and Primary Progressive Multiple Sclerosis

Business Wire April 26, 2017

FDA Grants Genentech’s TECENTRIQ (Atezolizumab) Accelerated Approval as Initial Treatment for Certain People with Advanced Bladder Cancer

Business Wire April 17, 2017

FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy, the Leading Cause of Blindness Among Working Age Adults in the United States

Business Wire April 17, 2017

Genentech Announces Positive Interim Results for Emicizumab in Phase III Study of Children with Hemophilia A

Business Wire April 17, 2017

Roche launches antibody test to aid in diagnosis of challenging prostate cancer cases

PR Newswire April 12, 2017

Roche launches new global Certified Provider Program for Target Enrichment in Genomic Sequencing

PR Newswire April 11, 2017

Phase III Study Shows Genentech’s Alecensa® Was Superior to Crizotinib in a Specific Type of Lung Cancer

Business Wire April 10, 2017

FDA Advisory Committee Unanimously Recommends Approval of Genentech’s Subcutaneous Rituximab for Certain Blood Cancers

Business Wire March 29, 2017

FDA Approves Genentech’s OCREVUS™ (Ocrelizumab) for Relapsing and Primary Progressive Forms of Multiple Sclerosis

Business Wire March 28, 2017

FDA Grants Breakthrough Therapy Designation for Rituxan® (Rituximab) in Pemphigus Vulgaris

Business Wire March 24, 2017

New MagNA Pure 24 System by Roche offers labs improved flexibility and automation

PR Newswire March 17, 2017

Roche launches the cobas® EGFR Mutation Test v2 for use with either plasma or tumor tissue samples

Canada NewsWire March 14, 2017

Roche Diagnostics recognizes Poplar Healthcare as Roche Molecular Center of Excellence

PR Newswire March 13, 2017

Here's What Analysts Are Asking Puma Biotech Following Roche's Positive Perjeta Results

Benzinga.com  March 2, 2017

Why Bermuda Could Be The Next Switzerland

Benzinga.com  March 2, 2017

Phase III APHINITY Study Shows Genentech’s Perjeta® Regimen Helped People with an Aggressive Type of Early Breast Cancer Live Longer Without Their Disease Returning Compared to Herceptin® and Chemotherapy

Business Wire March 2, 2017

New frontiers in cancer research and treatment to be explored by global experts at Tucson Symposium

PR Newswire Europe Non Regulatory February 27, 2017

Phase II Study Supports Potential for Genentech’s Tecentriq® (Atezolizumab) Plus Avastin® (Bevacizumab) for People With Locally Advanced or Metastatic Renal Cell Carcinoma

Business Wire February 18, 2017

Deutsche Bank Casts Doubt On Pfizer's Rumored Takeover Approach To Bristol-Myers

Benzinga.com  February 15, 2017